EThanol administration under intraoperative His bundle potential monitoring for the purpose of predicting and preventing the occurrence of complete Atrioventricular block in Percutaneous tRansluminal sEptal myocarDIal ablation for obstruCTive hypertrophic cardiomyopathy - ETHA-block-PREDICT study

Hiraya Daigo0 个研究点目标入组 20 人开始时间: 2022年10月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Hypertrophic obstructive cardiomyopathy
•2. Percutaneous transluminal septal myocardial ablation for left ventricular outflow tract obstruction
•3. Optimal medical therapy such as beta blockers, group I antiarrhythmic drugs, and calcium channel blockers
•4. Heart failure symptoms of NYHA IIm or higher, chest pain, or syncope
•5. Left ventricular pressure gradient of 50 mmHg or more by echo or catheterization
•6. Men and women over 40 years old
•7. After receiving sufficient explanation for participation in this study, consent document by the patient's free will was obtained with sufficient understanding

•1. History of percutaneous transluminal septal myocardial ablation and surgical myectomy
•2. Ventricular pacing after pacemaker or ICD implantation
•3. After aortic valve or mitral valve replacement
•4. After coronary artery bypass grafting
•5. Mainly obstruction in the mid-ventricle
•6. Untreated significant stenotic lesions in the coronary arteries
•7. Contrast allergy
•8. Bronchial asthma
•9. Cre 2.0 mg/dL or higher (Exclude dialysis cases)
•10. Severe alcohol hypersensitivity
•11. During pregnancy, or women who may be pregnant
•12. Patients judged by the investigator to be inappropriate as subjects

发起方

Hiraya Daigo